NCT05652543View on ClinicalTrials.gov

A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

518

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions
COVID-19 Pandemic
Interventions
BIOLOGICAL

SCTV01E

Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.

BIOLOGICAL

Placebo (normal saline)

Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.

Trial Locations (4)

210003

Jiangsu Center for Disease Control and Prevention, Nanjing

223400

Lianshui County Center for Disease Control and Prevention, Lianshui

225316

Taizhou Vaccine Clinical Research Center, Taizhou

635100

Dazhu County Center for Disease Control and Prevention, Dazhou

All Listed Sponsors
lead

Sinocelltech Ltd.

INDUSTRY